Insights on Oligometastatic Non-Small-Cell Lung Cancer

Valdivia A.; Mascaro-Baselga P.; Salva-de Torres C.; Geng-Cahuayme A.; Torresan S.; Yaringaño J.; Priano I.; Iranzo P.; Pardo N.; Masfarre L.; Mirallas O.; Farfan K.; Cedres S.; Rocha P.; Martinez-Marti A.; Felip E. · Cancers (2025) · DOI: 10.3390/cancers17152451

Resumen

Oligometastatic non-small-cell lung cancer (OMD-NSCLC) has emerged as a biologically and clinically distinct subtype of advanced disease, characterized by limited metastatic burden and a more indolent course. In this narrative review, we examine the current definition of OMD-NSCLC, diagnostic tests, possible biomarkers, and current therapeutic strategies. Biological insights highlight the role of microRNAs in differentiating true oligometastatic state from polymetastatic disease. The main local ablative therapies (LAT) include surgery and radiotherapy. The integration of LAT with systemic therapies has been explored in clinical trials, yielding promising but occasionally inconsistent results. As the therapeutic landscape of OMD-NSCLC patients continues to evolve, refining definitions, identifying predictive biomarkers, and individualizing care are essential steps toward achieving the potential of radical-intent therapy.